188 related articles for article (PubMed ID: 20576578)
1. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
2. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
3. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
4. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
5. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
[TBL] [Abstract][Full Text] [Related]
6. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
[TBL] [Abstract][Full Text] [Related]
8. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
[TBL] [Abstract][Full Text] [Related]
9. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
[TBL] [Abstract][Full Text] [Related]
10. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
[TBL] [Abstract][Full Text] [Related]
13. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
Lee SH; Kim MJ; Lee SH; Kim J; Park HJ; Lee J
Eur J Med Chem; 2011 Jul; 46(7):2662-75. PubMed ID: 21514014
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
15. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
17. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors.
Yan Q; Ding N; Li Y
Carbohydr Res; 2016 Feb; 421():1-8. PubMed ID: 26735747
[TBL] [Abstract][Full Text] [Related]
19. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
Pan X; Huan Y; Shen Z; Liu Z
Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
